Logo

Roche's Tecentriq (atezolizumab) + Avastin (bevacizumab) Receive the EC's Approval for Unresectable Hepatocellular Carcinoma

Share this

Roche's Tecentriq (atezolizumab) + Avastin (bevacizumab) Receive the EC's Approval for Unresectable Hepatocellular Carcinoma

Shots:

  • The approval is based on P-III IMbrave150 study involves assessing of Tecentriq (atezolizumab- 1200mg) + Avastin (bevacizumab- 15 mg/kg) on day 1 of each 21-day cycle vs sorafenib (400mg- bid) on days 1-21 of each 21-day cycle in 501 patients in a ratio (2:1) with unresectable HCC- prior not treated with systemic therapies
  • Result: reduction in the risk of OS (42%); reduction in the risk of disease worsening or death- PFS (41%); showed improvement in both OS and PFS; Grade 3–4 AEs (57% vs 55%)- published in the NEJM
  • The approval follows an EMA’s CHMP positive opinion received in Sept’2020. The dual regimen also recently included as a class I- A recommendation by the ESMO for unresectable HCC- as well as by many clinical practice guidelines globally

  Ref: Roche | Image: Roche 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions